Literature DB >> 15216857

Enterohemorrhagic Escherichia coli O157, Kinshasa.

Louis Koyange, Gaelle Ollivier, Jean-Jacques Muyembe, Benoit Kebela, Malika Gouali, Yves Germani.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15216857      PMCID: PMC3323201          DOI: 10.3201/eid1005.031034

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: During the rainy season, from April to September 2003, 463 children ≤15 years of age (median 10 months) with severe diarrhea were admitted to the Pediatric Hospital of Kalembelembe in Kinshasa, the capital of the Democratic Republic of Congo. The population of the outbreak area was approximately one million. Several children with bloody diarrhea without fever were treated. They came from six districts of Kinshasa (Bumbu, Selembao, Makala, Kimbanseke, Masina, and Ndjili). Abdominal cramps, nausea, vomiting, and dehydration were uncommon. The duration of illness ranged from 5 days to 2 weeks. Available antiparasitic drugs, trimethoprim-sulfamethoxazole, and ampicillin showed no effect against the illness. Fifty-six infants died between June and July. Symptoms of hemolytic-uremic syndrome developed in most of them. Stool samples from 32 patients were screened for parasites, enteropathogenic bacteria, rotavirus, and adenovirus. Three samples were positive for rotavirus. In contrast, all stool cultures were positive for Escherichia coli which always grew as pure cultures on purple bromocresol agar, a nonselective medium containing lactose. The E. coli isolates appeared sorbitol negative when tested on MacConkey sorbitol; they were agglutinated by O157 and H7 antisera (Difco Laboratories, Detroit, MI) and lacked expression of β-glucuronidase. All E. coli isolates were sent to the Pasteur Institute in Bangui, Central African Republic, for further characterization. Polymerase chain reaction allowed detection of Shiga-like toxin slt-1 and slt-2 genes (,) in isolates from all patients. The Vero cell assay phenotypically confirmed cytotoxicity of these isolates, with most of them being seroneutralized by rabbit antisera against Shiga toxin (). Thus, all E. coli isolates responded to the definition of enterohemorrhagic E. coli. Before 2003, sporadic infections or outbreaks caused by enterohemorrhagic E. coli were not reported as a cause of bloody diarrhea in the Democratic Republic of Congo. A case-control study could not be performed because of political unrest in Kinshasa. Although reported outbreaks of E. coli O157 in sub-Saharan Africa have been few to date, available information indicates that the pathogen has wide geographic distribution. E. coli O157–related diarrhea outbreaks that occurred before 2003 have been reported in South Africa, Swaziland (), and Malawi () in 1992; Central African Republic () and Kenya () in 1996; Cameroon in 1998 (); and Nigeria () and Ivory Coast () in 2000. In the Central African Republic and in Zémio, a small village located on the Democratic Republic of Congo border, outbreaks of bloody diarrhea in 1996 were attributed to E. coli O157 from molecular test results (). Since 2001, an increasing number of cases of acute bloody diarrhea have been reported in Kinshasa between June and August. During this 2003 outbreak, an investigation could not be conducted; possible routes of transmission would include person-to-person contact related to lack of hygiene, and contaminated food and water. In 1996 in the Central African Republic and in 1998 in Cameroon, the major contributing factors of the E. coli O157 outbreak were consumption of smoked zebu meat and contaminated drinking water. Studies of E. coli O157 carriage rates among livestock, food, and environment in this central African area might be useful in assessing the potential for future outbreaks. Hemolytic-uremic syndrome occurs in approximately 8% of children and an unknown proportion of adults infected with E. coli O157 and can be fatal without hemodialysis. The high death rate of infants during this outbreak was linked to the lack of treatment (mainly hemodialysis) at the beginning of the epidemic. Obviously, more work is needed to better define the incidence and epidemiology of E. coli–associated diarrhea in the Democratic Republic of Congo so that optimal recommendations for preventing and managing illness can be developed.
  10 in total

1.  Enterohaemorrhagic Escherichia coli in Ngoïla (Cameroon) during an outbreak of bloody diarrhoea.

Authors:  Y Germani; P Cunin; E Tedjouka; C B Ncharre; J Morvan; P Martin
Journal:  Lancet       Date:  1998-08-22       Impact factor: 79.321

2.  Enterohaemorrhagic Escherichia coli in Central African Republic.

Authors:  Y Germani; B Soro; M Vohito; O Morel; J Morvan
Journal:  Lancet       Date:  1997-06-07       Impact factor: 79.321

3.  Haemorrhagic colitis due to Escherichia coli O157:H7 in Kenya.

Authors:  W K Sang; S M Saidi; H Yamamoto; T Ezaki; T Iida; M Yoh; T Honda
Journal:  J Trop Pediatr       Date:  1996-04       Impact factor: 1.165

4.  Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis.

Authors:  S D Tyler; W M Johnson; H Lior; G Wang; K R Rozee
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

5.  Aetiology of haemorrhagic colitis epidemic in Africa.

Authors:  C Paquet; W Perea; F Grimont; M Collin; M Guillod
Journal:  Lancet       Date:  1993-07-17       Impact factor: 79.321

6.  Haemorrhagic colitis epidemic in Africa.

Authors:  M Isaäcson; P H Canter; P Effler; L Arntzen; P Bomans; R Heenan
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

7.  Prevalence of EHEC O157:H7 in patients with diarrhoea in Lagos, Nigeria.

Authors:  I D Olorunshola; S I Smith; A O Coker
Journal:  APMIS       Date:  2000-11       Impact factor: 3.205

8.  Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction.

Authors:  D R Pollard; W M Johnson; H Lior; S D Tyler; K R Rozee
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

9.  [Isolation of enteric pathogeic agents in Côte d'Ivoire: Escherichia coli O157:H7 and enteroaggregative E. coli].

Authors:  A Dadié; T Karou; N Adom; A Kétté; M Dosso
Journal:  Bull Soc Pathol Exot       Date:  2000-04

10.  Easy-to-perform modified Elek test to identify Shiga-like toxin-producing diarrhoeogenic Escherichia coli.

Authors:  Y Germani; E Begaud; J M Desperrier
Journal:  Res Microbiol       Date:  1994-05       Impact factor: 3.992

  10 in total
  5 in total

1.  Detection of infectious disease outbreaks in twenty-two fragile states, 2000-2010: a systematic review.

Authors:  Catherine Bruckner; Francesco Checchi
Journal:  Confl Health       Date:  2011-08-23       Impact factor: 2.723

Review 2.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

3.  Assessment of the Contamination of Some Foodstuffs by Escherichia coli O157 in Benin, West Africa.

Authors:  Honoré Sourou Bankole; Victorien Tamègnon Dougnon; Roch Christian Johnson; T J Dougnon; Boniface Yehouenou; Sylvain Kougblenou; Maxime Agonsa; Magloire Legonou; Thomas Dadie; Lamine Baba-Moussa
Journal:  Int J Microbiol       Date:  2014-11-24

4.  Development of a real-time PCR assay and comparison to CHROMagarTM STEC to screen for Shiga toxin-producing Escherichia coli in stool, Cape Town, South Africa.

Authors:  John B Kalule; Karen H Keddy; Anthony Smith; Mark P Nicol; Lourens Robberts
Journal:  Afr J Lab Med       Date:  2017-12-14

5.  Bacterial Contamination of Children's Toys in Rural Day Care Centres and Households in South Africa.

Authors:  Solanka Ellen Ledwaba; Piet Becker; Afsatou Traore-Hoffman; Natasha Potgieter
Journal:  Int J Environ Res Public Health       Date:  2019-08-13       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.